Effect of valsartan on the incidence of diabetes and cardiovascular events.

By J. McMurray, Rury R. Holman, S. Haffner, M. A. Bethel, B. Holzhauer, T. Hua, Yuri N. Belenkov, Mitradev Boolell, John B. Buse, B. Buckley and 44 more. New England Journal of Medicine, 2010

648 citations recorded by the source corpus.

BACKGROUND It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. METHODS In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. We then followed the patients for a median of 5.0 years for the development of diabetes (6.5 years for vital status). We studied the effects of valsartan on the occurrence of three coprimary outcomes: the development of diabetes; an extended composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina; and a core composite outcome that excluded unstable angina and revascularization. RESULTS The cumulative incidence of diabetes was 33.1% in the valsartan group, as compared with 36.8% in the placebo group (hazard ratio in the valsartan group, 0.86; 95% confidence interval [CI], 0.80 to 0.92; P<0.001). Valsartan, as compared with placebo, did not significantly reduce the incidence of either the extended cardiovascular outcome (14.5% vs. 14.8%; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.43) or the core cardiovascular outcome (8.1% vs. 8.1%; hazard ratio, 0.99; 95% CI, 0.86 to 1.14; P=0.85). CONCLUSIONS Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events. (ClinicalTrials.gov number, NCT00097786.)

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/4a98930f5c8d13f62f4fbfa89ef7b676148032a1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2012, background): “Diabetes may be prevented by treatment with ARBs and possibly ACE inhibitors.(197) Beta-blockers are not contraindicated in diabetes and are as effective in improving outcome in diabetic patients as in non-diabetic individuals, although different beta-blockers may have different effects on glycaemic”
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, result): “4 mmHg difference in blood pressure between the groups, there was no difference in death, myocardial infarction, stroke, and revascularization.(113) Similarly, in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial, telmisartan failed to reduce stroke and major cardiovascu”
Association between insulin resistance and the development of cardiovascular disease (2018, background): “and insulin sensitivity [117], however, in others, no beneficial effect has been shown [118].”